Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.50 |
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188035 | 1.00 | NR1H2 (0.56) | NR1H2NR1H3RIPK1RORCABCB1 | |
| SCHEMBL12668388 | 1.00 | NR1H2 (0.56) | NR1H2NR1H3RIPK1RORCABCB1 | |
| SCHEMBL12712926 | 0.95 | NR1H2 (0.53) | NR1H2NR1H3RIPK1RORCABCB1 | |
| SCHEMBL25326983 | 0.89 | NR1H2 (0.48) | NR1H2NR1H3RIPK1RORCABCB1 | |
| SCHEMBL12668394 | 0.89 | NR1H2 (0.48) | NR1H2NR1H3RIPK1RORCABCB1 | |
| SCHEMBL25326986 | 0.89 | NR1H2 (0.48) | NR1H2NR1H3RIPK1RORCABCB1 | |
| SCHEMBL25325447 | 0.88 | RIPK1 (0.53) | NR1H2NR1H3RIPK1RORCHTRA1 | |
| SCHEMBL25325443 | 0.88 | RIPK1 (0.53) | NR1H2NR1H3RIPK1RORCHTRA1 | |
| SCHEMBL12668399 | 0.87 | NR1H2 (0.49) | NR1H2NR1H3RIPK1RORCHTRA1 | |
| SCHEMBL4035101 | 0.87 | RIPK1 (0.64) | NR1H2NR1H3RIPK1RORCABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096149-B | Process for the preparation of beta-arylamines | 富兰克科技（深圳）股份有限公司 | 2021-02-26 | — | — | CN | claimed |
| CN-109096149-A | The preparation method of β arylamine | 富兰克科技（深圳）股份有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-109096149-B | Process for the preparation of beta-arylamines | 富兰克科技（深圳）股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-109096149-A | The preparation method of β arylamine | 富兰克科技（深圳）股份有限公司 | 2018-12-28 | — | — | CN | disclosed |
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016374-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | SLC6A5, SLC6A9, SLC6A19 | NR1H2 793/4885NR1H3 623/4885RIPK1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.